Down 13% from the year is high at £ 116.50 Now, the amount of astrazeneca looks cheaper anywhere under $ 219.81

AstrazenecaPrice Sharing Price Keeping up to the bottom from 3 September 12 sold for £ 133.38.

Such deduction can indicate that the giant is more important than ever.

Or can occur a large bargain to have.

To find out where, I looked at the basic business and its estimate.

What does the business look like?

Weighing a recently shared price for a continuous investigation in the Chinese Chinese Fort Service. This includes the allegations of fraudulent medical insurance, drugs and illegal drugs and personal information information. This is always a major risk in the company, in my view.

However, its full-year-old results issued on 6 February has shown a total of 21% of the year to year to $ 54.073bn (£ 43.599bn). Its EPPS earned (EPS) was up to 19% to $ 8.21.

The company also brought nine courses to the highest III class of the year. This is the last phase before treatment can get control permission to go to the market.

Atrazeneca is now forecasting full money to expand high percentage of higher digits in 2025. Additional projects will arise lower percentage will rise by two percent down at that time.

Overall, it means 2024 “Mark the beginning of the late, very rich company of our company”. Added is that “Important Step in Our Convention 2030 A Trimit Total Revenue by the Time Ten..

Following these numbers, analysis to predict that the money is not available will increase the 16.97% per annum until the end of 2027.

And it is the last found growth enables the amount of company budget (and allocation) above.

So, are stock protected now?

I compare the stock price for stock keys and their peers as a first part of its current sharing price.

In the Material-to-Foidings (P / E), astrazeneca is the lowest in 31.7, above NOVO NORDisk by 27.6. The fossils of peer group include Phase by 32.4, Eli Lilly by 74.7, and Abbbvie by 78.7.

Therefore, astrazeneca looks too cheap about this amount.

The same is true of its RATIO’s Ratio by 5.5 against 34 ratio. And is true of its ratio of 4.1 pricing compared to 4.1 peer rate compared to 4.1 peer rate.

The second part of the information prices looks where there should be stock, based on the future financial predications of Flow Floor.

Ported revenue analysis of money using some analystical statistics and my shares in 47% lower.

Therefore, the fair value of the stock is technical £ 219.81.

It may be low or higher than this because of the market vagaries, of course. But three important rates of infinity and a large discount on the DCF-Delied Value Value Confirm how cheap stock is now.

I will buy some shares?

Any significant Atravenena’s DIP share the Atrazeneca Sharing Property The most tempting I missed.

The company has the intentions of interesting growth, which I think will hit you. Because of this, its money may increase at least in accordance with the prediction of the commentator, in my view.

This should conduct its allocation of allocation (and allocation) over time.

As a result, I will be buying more stock shortly.